Short Interest in Bionomics Limited (NASDAQ:BNOX) Rises By 8.6%

Bionomics Limited (NASDAQ:BNOXGet Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 70,400 shares, an increase of 8.6% from the December 31st total of 64,800 shares. Based on an average trading volume of 230,100 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Bionomics in a research report on Thursday, December 7th.

View Our Latest Stock Analysis on BNOX

Hedge Funds Weigh In On Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Lynx1 Capital Management LP purchased a new stake in shares of Bionomics Limited (NASDAQ:BNOXFree Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 815,512 shares of the company’s stock, valued at approximately $2,202,000. Bionomics comprises about 1.5% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 12th largest position. Lynx1 Capital Management LP owned about 9.99% of Bionomics at the end of the most recent quarter. Institutional investors and hedge funds own 3.21% of the company’s stock.

Bionomics Stock Performance

NASDAQ BNOX opened at $0.97 on Thursday. Bionomics has a twelve month low of $0.87 and a twelve month high of $7.71. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $1.25 and a 200 day simple moving average of $1.91.

About Bionomics

(Get Free Report)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

Featured Stories

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.